JP2022536692A5 - - Google Patents

Info

Publication number
JP2022536692A5
JP2022536692A5 JP2021573442A JP2021573442A JP2022536692A5 JP 2022536692 A5 JP2022536692 A5 JP 2022536692A5 JP 2021573442 A JP2021573442 A JP 2021573442A JP 2021573442 A JP2021573442 A JP 2021573442A JP 2022536692 A5 JP2022536692 A5 JP 2022536692A5
Authority
JP
Japan
Prior art keywords
raav vector
vector according
raav
promoter
plasma kallikrein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536692A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037189 external-priority patent/WO2020252136A1/en
Publication of JP2022536692A publication Critical patent/JP2022536692A/ja
Publication of JP2022536692A5 publication Critical patent/JP2022536692A5/ja
Pending legal-status Critical Current

Links

JP2021573442A 2019-06-11 2020-06-11 調節不全の血漿カリクレインによって媒介される疾患の治療のための抗体のアデノ随伴ウイルスベクター送達 Pending JP2022536692A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860101P 2019-06-11 2019-06-11
US62/860,101 2019-06-11
PCT/US2020/037189 WO2020252136A1 (en) 2019-06-11 2020-06-11 Adeno associated viral vector delivery of antibodies for the treatment of disease mediated dysregulated plasma kallikrein

Publications (2)

Publication Number Publication Date
JP2022536692A JP2022536692A (ja) 2022-08-18
JP2022536692A5 true JP2022536692A5 (cg-RX-API-DMAC7.html) 2023-06-20

Family

ID=71995023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573442A Pending JP2022536692A (ja) 2019-06-11 2020-06-11 調節不全の血漿カリクレインによって媒介される疾患の治療のための抗体のアデノ随伴ウイルスベクター送達

Country Status (7)

Country Link
US (1) US20230038502A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983449A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022536692A (cg-RX-API-DMAC7.html)
CN (1) CN114207135A (cg-RX-API-DMAC7.html)
AR (1) AR119271A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115126A (cg-RX-API-DMAC7.html)
WO (1) WO2020252136A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020392243A1 (en) 2019-11-28 2022-06-16 Regenxbio Inc. Microdystrophin gene therapy constructs and uses thereof
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
US20250326861A1 (en) * 2020-09-15 2025-10-23 Regenxbio Inc. Vectorized lanadelumab and administration thereof
CA3094859A1 (en) * 2020-10-01 2022-04-01 Entos Pharmaceuticals Inc. Proteolipid vesicles formulated with fusion associated small transmembrane proteins
CN114790245B (zh) * 2021-01-25 2026-08-11 成都康弘生物科技有限公司 一种抗体及其用途
AU2022214914A1 (en) * 2021-01-28 2023-08-17 Astria Therapeutics, Inc. Plasma kallikrein antibodies and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
EP1737966B1 (en) 2004-04-02 2012-05-09 Board of Regents, The University of Texas System Cancer specific promoters
US9725485B2 (en) * 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
JP6091435B2 (ja) * 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
GB201206455D0 (en) 2012-04-12 2012-05-30 Royal Holloway & Bedford New College Gene expression
US9346872B2 (en) * 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
AU2014228765A1 (en) 2013-03-15 2015-10-15 Medimmune, Llc Palivizumab epitope-based virus-like particles
IL247942B (en) * 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
JP6754361B2 (ja) 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
CL2014003590A1 (es) 2014-12-30 2015-07-10 Univ Chile Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
JP6879486B2 (ja) * 2015-03-17 2021-06-02 フリーイェ・ユニヴェルシテイト・ブリュッセルVrije Universieit Brussel Fviiiおよびfix用の最適化された肝臓特異的発現系
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
US10190135B2 (en) 2015-10-27 2019-01-29 Celltheon Corporation Chimeric post-transcriptional regulatory element
AU2017248259A1 (en) 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
CN109844124B (zh) 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
ES3024357T3 (en) 2017-02-17 2025-06-04 Purdue Research Foundation Targeted ligand-payload based drug delivery for cell therapy
TWI753168B (zh) * 2017-05-22 2022-01-21 日商武田藥品工業股份有限公司 用於血友病b基因療法之編碼具有增強表現的重組fix變異體之病毒載體
KR20200067195A (ko) * 2017-10-18 2020-06-11 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항체 치료제

Similar Documents

Publication Publication Date Title
JP2020114235A5 (cg-RX-API-DMAC7.html)
JP2022524434A5 (cg-RX-API-DMAC7.html)
JP2021106619A5 (cg-RX-API-DMAC7.html)
JP2022033855A5 (cg-RX-API-DMAC7.html)
JP2022549380A5 (cg-RX-API-DMAC7.html)
JP2024016207A5 (cg-RX-API-DMAC7.html)
JP2025078652A5 (cg-RX-API-DMAC7.html)
JP2022535749A5 (cg-RX-API-DMAC7.html)
IL299325B1 (en) Variants of acid alpha-glucosidase and their uses
JP2022541070A5 (cg-RX-API-DMAC7.html)
JP2021534814A5 (cg-RX-API-DMAC7.html)
JP2023545424A5 (cg-RX-API-DMAC7.html)
JP2024099770A5 (cg-RX-API-DMAC7.html)
JP2022529631A5 (cg-RX-API-DMAC7.html)
JP2022523679A5 (cg-RX-API-DMAC7.html)
JP2023536902A5 (cg-RX-API-DMAC7.html)
JP2018522529A5 (cg-RX-API-DMAC7.html)
JP2023536618A5 (cg-RX-API-DMAC7.html)
JP2017512466A5 (cg-RX-API-DMAC7.html)
JP2022525302A5 (cg-RX-API-DMAC7.html)
JP2023554066A5 (cg-RX-API-DMAC7.html)
JP2023535620A5 (cg-RX-API-DMAC7.html)
JP2024506266A5 (cg-RX-API-DMAC7.html)
JP2024543001A5 (cg-RX-API-DMAC7.html)
JP2022551744A5 (cg-RX-API-DMAC7.html)